

Special Advertising Section

PHARMACY PRACTICE NEWS

Corporate Profiles

2025-2026

Amneal Pharmaceuticals

Central Admixture Pharmacy Services, Inc.

Fresenius Kabi

Grifols

Health Care Logistics

Long Grove Pharmaceuticals

Medi-Dose/EPS

Omnicell

WG Critical Care, LLC

Specialty Pharmacy Continuum

Pharmacy Technology Report

The profiles in this section were submitted and/or reviewed by the advertisers.

Amneal Pharmaceuticals

A Trusted Partner in Pharmacy Innovation and Supply

Headquartered in Bridgewater, N.J., Amneal Pharmaceuticals is a global biopharmaceuticals company committed to making healthy possible. With a diverse portfolio of more than 280 generic, biosimilar and branded pharmaceuticals, Amneal meets critical pharmacy needs, especially within hospitals, health systems and institutional care settings across the United States.

For more than 20 years, Amneal has built success on strong U.S. roots and global capabilities. The company operates FDA-approved manufacturing facilities in the United States, India and Ireland, ensuring a stable, secure supply chain. A key differentiator is Amneal's in-house expertise in developing and producing complex pharmaceuticals, which reduces reliance on third parties and ensures quality and value. These capabilities support multiple care settings, including acute, surgical, long-term and outpatient environments. With a focus on reliability, cost containment and clinical value, Amneal is a trusted resource for pharmacy professionals nationwide.

Supporting Pharmacies With a Growing and Ready-to-Use Injectables Portfolio

As one of the top five U.S. generic manufacturers by prescription volume, Amneal continues expanding its complex product offerings, including injectables and biosimilars. In 2024, the company reached a milestone with more than 40 commercial and injectable products available in the United States, many in ready-to-use formulations designed to improve pharmacy workflow and reduce medication preparation time.

Among these innovations is the debut of a multi-chamber flexible bag for hazardous drugs like cytotoxins and the first and only FDA-approved potassium phosphates in an IV bag. The portfolio is growing in prefilled syringes. These ready-to-administer formats help reduce the chances of dosage/administration errors, minimize hazardous exposure and enhance efficiency.



Addressing Critical Drug Shortages With Scalable Supply and Redundancy

Amneal's expanding injectables portfolio helps to fill gaps caused by shortages of critical products with limited or no alternatives. The company offers more than 10 injectable products currently on the ASHP shortage list. These include essential medications across oncology, anti-infectives and critical care.

Amneal has tripled its injectables and manufacturing capacity, reaching 60 million units across four facilities in the United States and abroad, ensuring continuous supply through built-in redundancy.

Looking ahead, Amneal expects to launch more than 60 commercial injectable products by 2026, strengthening its position as a core supplier for hospitals and clinics.

Robust In-House Capabilities for Complex Pharmacy Needs

Amneal brings in-house expertise in developing and manufacturing complex products, ensuring quality, scalability and competitive pricing without third-party dependence. The company's development capabilities span nearly all dosage forms, including complex oral solids, ophthalmics, liquids, topicals, inhalants, and transdermals and injectables.

Its biosimilars program also continues to grow, with three marketed products and two in development, targeting high-cost therapeutic areas with affordable alternatives.

Focused Institutional Support and Pharmacy Service

Amneal's Institutional Business Unit addresses the specific needs of hospital and health-system pharmacies. The team includes seasoned professionals experienced in group purchasing organizations, integrated delivery networks and acute care purchasing. Their goal is to deliver responsive service, product availability and value beyond transaction.

Amneal enhances operational efficiency through a dedicated online customer portal, allowing pharmacy buyers to place orders, manage invoices and track account status 24/7. The company also offers tailored

AT A GLANCE

400 Crossing Blvd.
Bridgewater, NJ 08807
(866) 525-7270
CustomerRelations@amneal.com



support for group purchasing organization contract compliance, 340B program navigation and formulary alignment, helping pharmacy teams optimize purchasing strategies.

Unwavering Commitment to Quality

Amneal's culture of quality is foundational across its global network. From development to delivery, the company meets or exceeds FDA, global regulatory and internal performance standards. Pharmacy professionals can trust that each Amneal product is backed by rigorous testing, continuous improvement practices and a company-wide dedication to safe, effective medications.

Making Healthy Possible

With more than two decades of innovation and service, Amneal is much more than a generics manufacturer. Today, it is better positioned than ever to meet essential medical needs, expand access to quality medicines and deliver solutions for tomorrow's health challenges. Employees often say it's just one of the many ways they help "make healthy possible."

As healthcare evolves, Amneal remains committed to supporting pharmacy teams as essential partners in safe, effective and accessible care delivery.



We make healthy possible.

Central Admixture Pharmacy Services, Inc.

Quality, for life.

As the nation's largest network of outsourcing admixture pharmacies and a leading provider of 503A and 503B compounded sterile preparations (CSPs), Central Admixture Pharmacy Services (CAPS®) understands the importance of reliable access to high-quality medications. Our team of experts is passionate about providing just that, while also simplifying your operations by reducing the risks, costs and resource demands of in-house compounding.



Above all, your patients are at the center of everything we do. And as your trusted partner, we're committed to providing the products that help them live healthier, more secure lives.

Committed to Improvements

At CAPS, we're consistently working on our unique portfolio of products to address the most complex therapeutic uses. With a dedication to improvement, we design our patient-specific and batched, non-patient-specific CSPs to best meet critical patient needs and be compatible with the most up-to-date infusion devices.

Transparent Communication

CAPS is committed to improving transparent communication to help address medication management planning across our products, which include quality assurance (QA) customer service reports, drug shortages, product availability dates and new product releases. We've designed a vertical supply chain integration to address any ongoing shortages of key medications with limited commercially manufactured options.

Products and Services

- **CAPSLink™:** The only HITRUST-certified portal, featuring a secure back-end architecture specifically designed to reduce the risk for unauthorized access to customer data. Additionally, our secure, encrypted electronic ordering system adheres to HIPAA standards for patient-specific parenteral nutrition (PN) therapy. Our electronic health record interface is transcription-free, eliminating manual order entry, so you can have confidence in your patients' safety.
- **CAPS Parenteral Nutrition Data Analytics Service:** Better data can help you discover opportunities to become more efficient at your facility. Our data analytics service helps with everything from PN dosage benchmarking and

operational efficiencies to identifying variables that drive ingredient waste and the options to minimize it. We use tools that can benchmark to American Society for Parenteral and Enteral Nutrition recommendations and identify high-cost additive usage to optimize efficiency across prescribers, facilities and systems at the national level.

- **CAPS Parenteral Nutrition Training Program:** Created and presented by a board-certified nutrition support pharmacist, this program focuses on the unique challenges involved in treating adult patients who need PN. The four, 60-minute interactive webinar sessions will cover topics like PN indications, drug therapies and PN formulation changes, vascular access, and more. The program also includes lectures supplemented with case studies, discussion and Q&A, and a competency exam at the conclusion of the training.

Proven Quality

CAPS is a national network of USP <797>-compliant 503A pharmacies and FDA-registered 503B outsourcing facilities that adhere to Current Good Manufacturing Practices (cGMPs). Our goal is to provide the most comprehensive and continuous QA program in the industry, so you can help more patients get access to the safest, most reliable treatment possible and reassured quality for life.

Product Integrity

We prioritize the integrity of our compounded products and processes every step of the way. Our outsourcing facilities have obtained drug distributor accreditation by the National Association of Boards of Pharmacy (NABP). And, our automated electronic batch record also ensures that all SOPs and applicable quality indicators are fully compliant prior to each batch release, while also improving efficiency.



AT A GLANCE

6430 Oak Canyon
Suite 200
Irvine, CA 92618
Telephone: (949) 660-2277
Toll-free: (800) 853-6498
marketing@CAPSpharmacy.com

Test, Hold & Release (THR®) is a key component of our QA program that integrates cGMP-level end product testing with the release process for our 503B compounded drugs. This program ensures that every compounded drug batch from our 503B outsourcing facilities meets strict specifications for sterility, endotoxin and potency release testing before it reaches you and your patients.

GPO Trusted

We believe that good partnerships go a long way for the quality and accessibility of our products, which is why CAPS has a long-term relationship with the largest group purchasing organizations (GPOs) to ensure contract access regardless of affiliation. This helps with potential cost savings, streamlined supply chain and regulatory compliance.

Backed by B. Braun

CAPS is proud to be backed by B. Braun, a leader in effective pharmaceutical and medical device manufacturing, patient and provider safety, and sustainable health solutions. Invested in CAPS research and development, B. Braun continuously supports our work to expand our product portfolio to meet the ever-changing needs of customers.

Together, we share a mission to double the number of patients we touch. Because when lives are on the line, providers like you should be able to get the best care for as many patients as possible.

To learn more, visit capspharmacy.com.



Fresenius Kabi

Fresenius Kabi is a global healthcare company “Committed to Life.” The company’s products, technologies and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi offers an expansive product portfolio that focuses on providing access to high-quality and lifesaving medicines and technologies.

Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912.

Our commitment to more supply, science and support in the United States is a reason our customers can deliver patient care with more confidence. Since 2017, Fresenius Kabi has invested nearly \$1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. More than 70% of the units shipped by Fresenius Kabi in the United States are drugs listed on the FDA’s Essential Medicines List.¹

We continue to expand our suite of ready-to-administer offerings to assure pharmacists and nurses have a wide range of prefilled, standard strengths,

single-patient delivery systems options—from bags to syringes—that streamline medication management from the pharmacy to the bedside and eliminate steps where errors can occur.

In addition to pharmaceutical products, Fresenius Kabi offers biosimilars for immunologic diseases and oncology treatments. The company also has a leading market position in lipids within clinical nutrition in the United States; in MedTech, the company provides infusion pumps, cell and gene therapy devices, and disposables; and is a global leader in supplying blood collection bags and devices and supporting blood banks and other healthcare sites.



AT A GLANCE

Three Corporate Drive
Lake Zurich, IL 60047
(888) 391-6300
communications.USA@fresenius-kabi.com
www.fresenius-kabi.com/us

For more information about Fresenius Kabi, please visit www.fresenius-kabi.com/us or www.moreinamerica.com.

To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/careers and follow us on LinkedIn and Facebook.

Reference

1. Data on file. 2023. <https://www.fda.gov/media/143406/download>



Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 and committed to improving the health and well-being of people around the world. The company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.



As fundamental corporate values, quality and safety are fostered by Grifols' corporate culture and integrated into every stage of the value chain. The company's vertically integrated business model further enhances its control over production processes.

Biopharma

A pioneer in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. To ensure a safe and consistent source of plasma-derived medicines worldwide, we have a vertically integrated production process from plasma collection through fractionation and purification at our facilities in the U.S. and Spain. Key essential plasma-derived medicines treating patients include immunoglobulins, alpha₁-antitrypsin, albumin, clotting factors, and specialty hyperimmune globulins.

Diagnostic

As a recognized leader in transfusion medicine and trusted provider to blood banks and hospitals, Grifols offers a comprehensive portfolio of products that includes solutions to ensure blood compatibility and detect possible pathogens in donors of blood, plasma and tissues, while also simplifying laboratory operations. In addition, the company provides solutions for clinical diagnostics focused on selected therapeutic areas.

Bio Supplies

Grifols also offers high-quality biological supplies for life-science research and for in vitro diagnostic companies in the manufacturing of reagents and controls. This includes whole blood, blood components, processed plasma, and clinical samples. The company also provides a comprehensive portfolio of human plasma products to pharmaceutical and biotechnology companies for further manufacturing. Grifols collects biological materials from its own network of blood and plasma centers in the U.S. and Europe.



AT A GLANCE

2410 Grifols Way
Los Angeles, CA 90032
(888) 474-3657
grifols.com

Other Healthcare Solutions

INCLUSIV™ from Grifols is a comprehensive, integrated portfolio of proven technology, software and services designed to meet the safety and compliance challenges of sterile compounding preparation, while optimizing operational efficiencies. INCLUSIV encompasses cleanroom engineering design and construction, IV robotic systems, pharmacy operations software, and specialized disposables.

Grifols, Commitment to Sustainability

Grifols, recognized as one of the world's most sustainable companies, works to make a positive social and economic impact on society, including local jobs and social value creation for donors, patients, and communities. Aligned with the United Nations plan to achieve the Sustainable Development Goals defined in its 2030 agenda, the company challenges itself every day to do more and do better to contribute to the health and quality of life of people everywhere.

Normal Saline

Grifols provides 0.9% Sodium Chloride for 500 mL injection in the U.S. The commercialization of Grifols Normal Saline represents an important step forward to mitigate the current shortage that hospitals have been facing since 2014. Grifols Sodium Chloride is provided in the Fleboflex® container that is made with polypropylene and is free of PVC, DEHP, and latex.

GRIFOLS

Health Care Logistics

Special Answers to Special Problems

What began in 1978 as a garage-based business at the home of Health Care Logistics® (HCL®) owner Gary Sharpe now encompasses five well-equipped facilities in central Ohio and reaches customers around the globe. Employment has grown too, with more than 300 employees now dedicated to the company's mission of providing unmatched customer service.



Mr. Sharpe discovered early in his career the need for healthcare products in sizes, quantities and materials not readily available and was determined to deliver.

And has he ever.

Today, HCL's inventory includes more than 9,000 different products all designed to provide "Special Answers to Special Problems." The majority of these items are maintained locally in more than 320,000 square feet of warehouse space and meet the supply needs of hospitals, pharmacies, chain drugstores, pharmaceuticals and many other facets of healthcare.


Now under the day-to-day direction of Mr. Sharpe's children, Kyle Sharpe and Bethany Sharpe Reid, co-presidents, the company continues to thrive.

"There are over 49,000 locations in all 50 states and 30 countries using items from Health Care Logistics, and that number keeps growing," Mr. Sharpe said. "It really makes us excited to see our products so widely used."

If a product isn't on the warehouse shelves, it simply means it isn't available yet.

HCL also offers complimentary search and development services for non-inventory items customers want but can't find.

Product scouting is just one example of the unmatched service the company provides every customer, every day. Together with small product quantities, same-day shipping and hassle-free returns, they are the pillars on which the company stands.



AT A GLANCE

450 Town Street
Circleville, OH 43113
Toll-free: (800) 848-1633
Toll-free fax: (800) 447-2923
hcl@gohcl.com
gohcl.com

"Customer service is at the heart of what we do," Ms. Reid said. "We work closely with our customers to recognize needs. We seek the right solutions—not just the easy solutions—and create win-win situations for all."

The company's manufacturing division encompasses 120,000 square feet of space dedicated to making exactly what its customers need. Because production capabilities are virtually unlimited, HCL is able to help healthcare professionals solve problems and improve performance, accountability and reliability in ways previously unthinkable.

"We are committed to complete product development from concept design to manufacturing and ongoing support," Mr. Sharpe said. "From our first contact with our customers to the time their products are delivered and thereafter, we are dedicated to providing ideal solutions to their unique needs."

Ms. Reid agrees and gives credit for much of the company's growth and success to the collaboration of multiple departments.

"At HCL we are not afraid to try, fail, adjust and try again," she said. "This process is all part of creating better solutions for our customers. Our departments do not operate as silos. It is very common for every project to have representation from at least three different areas."

"Your Way, Right Away" is the philosophy that keeps business going strong to meet individual customer requests. HCL has developed proven systems and manufacturing processes that allow it to quickly and cost-effectively solve problems for its customers, and its potential is limitless.

Well equipped, well staffed and well represented across the country and beyond, HCL—like Gary Sharpe in 1978—is determined to deliver.



Long Grove Pharmaceuticals

Sustaining a safe and reliable pharmaceutical supply chain

Long Grove Pharmaceuticals was founded in 2019, with a commitment to bring together experienced people, develop efficient processes, and deliver needed products for patients and providers. We introduced our first product to customers in 2022. The company is improving the fragile generic supply chain by developing complex formulations, addressing manufacturing challenges and achieving regulatory approvals in difficult environments.

Combining decades of pharmaceutical and hospital leadership experience with a portfolio of specialized, complex drug formulations, Long Grove Pharmaceuticals provides differentiated products that increase hospital pharmacy operational efficiency and help improve the quality of patient care.

The Long Grove Pharmaceuticals website (longgrovepharma.com) provides the most up-to-date product information. FDA-approved products from Long Grove include:

- Premix Norepinephrine Injection: Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting. Norepinephrine in 0.9% Sodium Chloride in 4 mg/250 mL (16 mcg/mL), 8 mg/250 mL (32 mcg/mL) and 16 mg/250 mL (64 mcg/mL) are currently available.
- Premix Vasopressin Injection: Vasopressin is a critical care medication used to increase blood pressure for patients in critical hypotensive shock when other measures have failed. Long Grove Pharmaceuticals offers 20 units/100 mL (0.2 units/mL) in 0.9% sodium chloride and 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride.

Long Grove Pharmaceuticals also has the following products available:

- AK-FLUOR® (Fluorescein Injection, USP)
- Carboprost Tromethamine Injection, USP
- Cyclophosphamide for Injection, USP
- Eribulin Mesylate Injection
- Sodium Bicarbonate Injection, USP
- Triamcinolone Acetonide Injectable Suspension, USP

Reducing Risks

Improving the availability of FDA-approved, premix pharmaceuticals plays an essential role in enhancing pharmacy operations and eliminating certain risks that are inherent in the compounding process. Long Grove Pharmaceuticals has a robust and growing pipeline. The company will continue to innovate across therapeutic categories in the years ahead, and every employee is committed to meeting the needs of patients and providers, ensuring safe supply integrity, and working to prevent drug shortages.

The extensive hospital pharmacy and generic pharmaceutical experience within the company drive the commitment to meet customer and patient needs. This dynamic company is improving the fragile pharmaceutical supply chain by developing complex formulations, addressing manufacturing challenges and achieving regulatory approvals in difficult environments. The Long Grove Pharmaceuticals team brings together decades of pharmaceutical expertise to create collaborative and reliable partnerships with manufacturers, developers, suppliers and customers.

“We are deeply committed to leveraging our knowledge and integrated corporate structure to continuously fulfill a range of unmet needs in the generic pharmaceutical industry,” said Peter Karas, the chief commercial officer.

Long Grove Pharmaceuticals has proven expertise in rapidly bringing much-needed 505(b)(2) products to market. Depending on the need and unique manufacturing requirements, Long Grove Pharmaceuticals has trusted partnerships with established manufacturers in North America, Western Europe and Asia.

AT A GLANCE

9450 West Bryn Mawr Avenue
Suite 200
Rosemont, IL 60018
longgrovepharma.com

Long Grove Pharmaceuticals has a presence at most national and regional conferences and meetings for hospital pharmacists, group purchasing organizations and suppliers. We are always happy to have a conversation to understand how we can best meet our customers' needs.

“We believe that collaborative and reliable partnerships with manufacturers, developers, suppliers and customers are essential in relieving the country's drug shortage crisis,” said Mike Calsin, the vice president of Sales and National Accounts. “We're very happy to help play a role in relieving some of the stresses that our hospital pharmacy colleagues face every day. We meet with many customers on a regular basis who share their ongoing challenges, and they have been very supportive of our efforts to bring safe, convenient premix formulations to market.”

Please visit longgrovepharma.com for the latest product availability information.



Medi-Dose/EPS

For more than 50 years, the Medi-Dose System has been used by facilities of all sizes to package solid oral, unit-dose medications. With input from pharmacists and technicians, Medi-Dose has been designed to be the easiest, fastest and most cost-effective way to unit-dose and barcode your inventory.

Medi-Dose began in 1971, when Milton Braverman, a former pharmaceutical company territory manager, formed his own company. Robert Braverman, president, remembers: "My dad was acutely aware of the requirements of hospital pharmacy. He saw the need for inexpensive, manual unit-dose packaging allowing hospitals to convert from traditional dispensing. He developed systems to package, handle and dispense predetermined amounts of medication so they would be accessible for one regular dose."

Although familiar today, launching the unit-dose packaging was a huge problem the new company faced. "We were one of the pioneers, the innovators promoting unit dose in hospitals," Mr. Braverman recalled. "Due in part to Medi-Dose's educational efforts, pharmacists and nurses accepted the validity of unit dose."

Inexpensive, Easy and Flexible

Because of its unique Cold-Seal technology, the Medi-Dose System is simple to use and requires no special in-service training or additional space. Medi-Cup Blisters are available in 15 styles and eight sizes to accommodate the largest medications or the smallest storage spaces, and are particularly ideal for USP <800> medications. Ultraviolet-inhibitant blisters provide additional protection from light. Plus, a combination of special blister plastics with aggressive tamper-evident label adhesives provides either six-month or one-year beyond-use dating for all your unit-dose packaging needs.

The Medi-Dose System offers these additional benefits:

- Sealed units can be left in sheets or easily torn down to individual doses.
- Lid-Label Covers are available in 8" x 11" laser sheets of 25 doses or 4" x 6" direct thermal sheets of five doses.
- Laser Lid-Label Cover Sheets are available in a wide variety of colors to facilitate color coding of medications.
- Circular and Oval Blisters have been designed to fit your dispensing machines and storage cabinets.
- MPB® - Multi-Purpose Blisters allow you to easily package, label and secure even more sizes and types of medications, including large medications, compounded drugs, double and triple "O" capsules, unit-of-use packaging, repackaged medications, and suppositories.
- New Detect-A-Dose™ Lid-Label Covers provide quick visual identification of packaged meds within Medi-Cup Blisters.
- All Medi-Cup Blisters and Lid-Label Covers work with our MILT 4 Software, which can be used for all your barcoding and labeling needs.

Adapts to Your Needs

With our MILT 4 Software, you can design your labels any way you want (for solids, liquids, syringes, ampules,




Brightly colored Lid-Label Covers call attention to medications requiring special handling.

IVs—even equipment and supplies). In addition to the ability to use graphics, special fonts and shapes—even logos and symbols—to better identify your medications, MILT 4 has been designed to easily create barcodes with the information your barcode-enabled point-of-care and barcode medication administration systems require. Popular 1D and 2D barcode formats can be created with National Drug Code numbers, beyond-use dates, lot numbers and special codes. Plus, MILT 4 suggests tall man lettering options (e.g., DOPamine instead of DOPAMINE) for medications as recommended by the FDA and Institute for Safe Medication Practices. In addition, newly entered and previously saved medication names are compared with the CDC's "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings." If a match is found, the user is notified that this medication may potentially be hazardous to handle.

To get started, all you will need is:

- Medi-Cup Blisters: 15 styles to suit your packaging needs



New Detect-A-Dose Lid-Label Covers provide quick visual identification of packaged meds.

AT A GLANCE

70 Industrial Drive
Ivyland, PA 18974
Phone: (800) 523-8966
Fax: (800) 323-8966
info@medidose.com
medidose.com

- Lid-Label Covers: laser or direct thermal labels to seal the blisters
 - MILT 4 Software: design and manage Lid-Label Cover printing
 - Fil-Form Template and Roll-E-ZY Press Piece: aligns Lid-Label Covers to Medi-Cup Blisters, ensuring a positive seal between labels and blisters
- Inexpensive. Flexible. Tamper-Evident. If you are looking for a system to handle any or all of your unit-dose or barcoding needs, then the Medi-Dose System is the perfect fit for you!



Using our MILT 4 Software, you can label and identify all your medications, complete with graphics and a barcode.

Products

- Medi-Dose® (solid) and TampAlerT® (liquid) Oral Unit-Dose Packaging
- Medi-Cup® PLUS packaging for extended beyond-use dating
- MILT® by Medi-Dose unit-dose and barcoding software
- LiquiDose® labeling, IV additive and filtration products
- Nutraviolet® ultraviolet-inhibitant bags
- Steri-Dropper sterile ophthalmic dropper bottles
- High Alert and IV Line Tracing Labels
- Resealable bags, bottles, and other pharmacy supplies and disposables



Delivering Enhanced Medication Management Outcomes

Health systems are defined by outcomes: financial performance, employee satisfaction and retention, and most importantly, the quality of patient care. But achieving impactful outcomes can be a challenge, especially in today's environment of consolidation, workforce challenges, cybersecurity risks and care shifting beyond the four walls of the hospital.

Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business results across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics—all optimized by expert services—Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control and support compliance.

Whether automating medication management in the central pharmacy, consolidated pharmacy services center or cleanroom; streamlining medication dispensing at points of care; or optimizing specialty and outpatient pharmacy services, Omnicell solutions are helping our healthcare partners move closer to the industry-defined vision of the Autonomous Pharmacy.

Central Pharmacy Dispensing

Central pharmacy is the medication dispensing hub of every hospital. Roadblocks here affect patient safety, care and clinical workflows throughout the health system. Whether in a traditional health-system pharmacy or a consolidated services center setting, Omnicell solutions are helping to automate manual dispensing tasks to reduce errors and waste, improve accuracy, and free staff to focus on higher-value activities. Advanced robotic technology, optimization software, and on-site and remote experts combine to reduce human error, automatically track and optimize inventory, and minimize dispensing discrepancies. Health systems that leverage Omnicell's central pharmacy solutions are seeing a 75% reduction in pharmacist time spent on manual distribution tasks.



IV Compounding

Accuracy and sterility are paramount in IV compounding, but an overreliance on 503B outsourcing and manual in-house processes creates unnecessary risk and expense. Omnicell provides the automation tools and services to support a safer, more accurate and cost-effective in-house IV pharmacy. Sterile compounding robotics, semiautomated workflow technology, software and expert services are helping health systems reduce outsourcing costs, minimize OR waste and gain supply chain control. One health system realized \$1.5 million in annual savings by insourcing sterile compounding operations via a partnership with Omnicell.

Points of Care

The administration of medication at the patient's bedside is the final step in the pharmacy delivery process in an inpatient setting. Countbacks, restocks, reconciliation and other manual tasks can extend the time nurses spend managing medications, taking their focus away from clinical care. Market-leading automation, intelligent software and expert support to optimize medication management are helping to streamline workflows for both nurses and pharmacists, allowing clinicians to spend more time caring for patients. One health system has reduced nursing time at the cabinet by 54% because of Omnicell automation.

Inventory Optimization

Managing medication inventory can be a tedious task fraught with challenges, such as expiring medications, par level tracking, labor shortages and potential

AT A GLANCE

Learn more about how Omnicell is defining and delivering outcomes at omnicell.com.

controlled substance misuse. Omnicell offers comprehensive solutions combining advanced software, robust benchmarking, predictive and prescriptive analytics, and clinical experts to identify and execute potential inventory optimization opportunities. Enhanced inventory visibility and optimization helped one health system achieve \$1.2 million in medication cost savings within 12 months of implementation.

Specialty Pharmacy

As medical innovations create new, more complex drugs, pharmacies need specialized tools and expertise to help manage the patient's treatment journey. Opening or optimizing an entity-owned specialty pharmacy requires unique capabilities to navigate the demands of high-cost, high-touch medications. Omnicell delivers the technology and know-how to establish, manage and optimize an entity-owned specialty pharmacy, helping accelerate and maximize their outcomes. With this turnkey solution, a new specialty pharmacy program can become cash-flow positive in as little as six months.

Retail Pharmacy Solutions

Truly optimizing a patient's medication journey means extending beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Omnicell offers a full suite of services to automate financial activities and deliver digital omnichannel patient-engagement solutions to transform clinical and business results. Retail pharmacies are realizing improved operational efficiency and improved patient medication adherence from Omnicell's solutions. For example, patients enrolled in our Med Sync engagement solution were three times more adherent, helping improve health outcomes and reduce hospital admissions.

Why Omnicell?

Omnicell is focused on delivering scalable solutions that are designed to grow visibility, enhance intelligence and streamline workflows, ultimately helping to close gaps in medication management across the care continuum.

Learn more about how Omnicell is defining and delivering outcomes at omnicell.com.



WG Critical Care, LLC

Customer-Centric Focus Invested in Delivering Patient Safety and Pharmacy Workplace Efficiency

WG Critical Care, LLC is a pharmaceutical company supplying innovative, FDA-approved, ready-to-use products, including a comprehensive line of beta-lactams. Our portfolio consists of 29 products selling 35 million units annually (based on IQVIA reported data).

From product concept to final dose, WG Critical Care offers industry-leading products that increase pharmacy workplace efficiency and enhance patient safety. Our track record includes first-to-file FDA-approved products critically needed by hospitals.

Patients are the ultimate beneficiaries of everything we do while pharmacy enables the successful delivery of our products to the bedside. Our products have features that reduce waste, risk of medication errors and medication preparation time, while saving pharmacy resources. These features include product stability of at least 24 months, preservative-free formulations, color-coded labeling and optimal package size to fit automated dispensing cabinets.

Building a Reliable and Consistent Supply Chain

At WG Critical Care, we understand the serious challenges hospitals face due to drug shortages. These

disruptions can compromise patient care and strain healthcare systems. Reliable supply is our part of the solution.

From sourcing active pharmaceutical ingredients to producing the finished product, we strictly adhere to Current Good Manufacturing Practices. Reliability in our supply chain is built on manufacturing redundancy. The majority of WG Critical Care products can be made in multiple FDA-approved manufacturing plants. In addition, we maintain strategic inventory reserves to help meet existing customer demand and unexpected surges in market demand.

At every step, WG Critical Care is focused on one goal: making sure the medications you need are available when you need them.

Providing Thought Leadership

At WG Critical Care, we focus on initiatives that advance hospital pharmacy practice in general. To assist

AT A GLANCE

120 Route 17 North
Paramus, NJ 07652
www.wgcriticalcare.com

hospital pharmacies in making informed decisions regarding the sourcing of ready-to-use bags for infusion, we are conducting a fact-based study that compares in-house compounding versus external sourcing of infusion bags. Findings will be available for hospital pharmacy decision-makers and other interested parties to review and apply.

Learn more about our products and company at www.wgcriticalcare.com.



READY-TO-USE FIRST AND ONLY!

Diltiazem Hydrochloride
in 0.72% Sodium Chloride Injection

100 mg per 100 mL
(1 mg per mL)

READY-TO-USE

NOREPINEPHRINE
Bitartrate in 0.9% Sodium Chloride Injection

4 mg/250 mL (16 mcg/mL)	8 mg/ 250 mL (32 mcg/mL)	16 mg/250 mL (64 mcg/mL)
-----------------------------------	------------------------------------	------------------------------------

READY-TO-USE

MIDAZOLAM[®]
in 0.9% Sodium Chloride Injection

50 mg per 50 mL (1 mg per mL)	100 mg per 100 mL (1 mg per mL)
---	---

Meropenem
for Injection, USP

2 grams per vial

FIRST AND ONLY!

READY-TO-USE

CALCIUM GLUCONATE
IN SODIUM CHLORIDE INJECTION

1,000 mg per 100 mL (10 mg per mL)	1,000 mg per 50 mL (20 mg per mL)	2,000 mg per 100 mL (20 mg per mL)
--	---	--

READY-TO-USE

ESMOLOL HCL
IN WATER FOR INJECTION

2,500 mg per 250 mL (10 mg per mL)	2,000 mg per 100 mL DOUBLE STRENGTH (20 mg per mL)
--	---

Specialty Pharmacy Continuum

For more than a decade, *Specialty Pharmacy Continuum* (SPC) has been tracking the rising trend that is specialty pharmacy. SPC continues to be a powerful addition to the *Pharmacy Practice News* editorial franchise, featuring essential clinical and business developments for managed care, health-system and specialty pharmacy/infusion provider decision-makers.

Core Topics

The breadth of topics SPC covers shows our dedication to meeting the information needs of our audience. Clinical expertise is critical to a specialty pharmacy's success, so we cover all the key disease states, including cystic fibrosis, hemophilia, hepatitis, HIV/AIDs, inflammatory conditions and oncology. But delivering those services in an efficient and cost-effective manner also is important. To that end, SPC tracks the latest trends in the following operational areas:


- Accreditation
- Cold chain and remote temperature monitoring
- Contracting with payors and other managed care stakeholders
- Copay and coupon programs
- Drug pricing/utilization
- Home infusion
- Managing drug spending
- Navigating the federal 340B Drug Discount Program
- Patient assistance programs
- Site-of-care optimization
- Sterile compounding compliance
- Understanding state and federal healthcare policies and the latest updates from practice standards organizations

Conference Coverage

To ensure SPC is tracking the latest developments in specialty pharmacy, our editors and reporters attend a wide range of conferences throughout the year, including those convened by AMCP, Asembia, MHA, NASP and NHIA, among others.

Conference News Missed that last pharmacy meeting?

Read all about it via the "Conferences" tab at SpecialtyPharmacyContinuum.com.



A central tenet of our meeting coverage is to file late-breaking news articles from sessions each day. So at each meeting, we sent out a Dispatch e-Newsletter featuring that content.

Of course, not all readers of SPC can travel to the specialty pharmacy meetings. But you don't have to miss out: All of our meeting coverage is easily accessed via the Conference News tab on our home page. Just choose that tab, click on the meeting you'd like to read about, and access our new and video coverage.

More Digital Offerings

SPC sends out thrice-weekly e-Newsletters featuring timely news, along with a monthly top 5 e-Newsletter highlighting SPC's most read articles. Our online offerings also include video interviews with leading specialty pharmacists and managed care executives.

Be Heard!

We welcome contributed articles, so if you are a clinical expert or an operational whiz, we'd like to hear from you. Send your topic ideas to davidb@mcmahonmed.com and we will help you share your insights.

AT A GLANCE

545 W. 45th Street, 8th Floor
New York, NY 10036
Phone: (212) 957-5300
Fax: (212) 957-7230
pharmacypracticenews.com

VP EDITORIAL

David Bronstein
davidb@mcmahonmed.com

GROUP PUBLICATION DIRECTOR

Dave Kaplan
dkaplan@mcmahonmed.com
(973) 885-2315

SENIOR EDITOR

Marie Rosenthal
mrosenthal@mcmahonmed.com

DEPUTY MANAGING EDITOR

Kate Baggaley
kbaggaley@mcmahonmed.com

MANAGER, PUBLICATION SALES

Lillie Onday
londay@mcmahonmed.com
(732) 979-7009



2024 Bronze Award Winner

Are FDA Fast-Track
Drugs Safe? Delayed
Data Raise Concerns



Pharmacy Technology Report

This supplement to *Pharmacy Practice News (PPN)* and *Specialty Pharmacy Continuum (SPC)* covers best practices in automation, informatics and patient safety. Our mission is to give health-system and specialty pharmacists the information they need to provide technology-enhanced, high-quality patient care in the most cost-effective manner possible.

Featured Content

Pharmacy Technology Report (PTR) focuses on automated dispensing, robotics, clinical decision support, telepharmacy, remote temperature monitoring and other key pharmacy technologies.

Our June 2025 issue included articles on whether current IV workflow management system adoption rates are enough to ensure patient safety; an award-winning plan for using dashboards to proactively manage drug shortages; and how to choose third-party 340B software to enhance split billing and other tricky payment challenges. (See June 2025 cover shot below right for more topics.)

Cyberattacks, Cold Chain and More

PTR covers other “hot” pharmacy technologies. Here are a few examples from prior issues:

- how to respond when a cyberattack results in significant downtime for your health system;
- cold chain shipping of cell and gene therapies;
- a new digital marketplace for purchasing medications that are in short supply; and
- new data showing that using gravimetric workflow to verify medication preparation boosts accuracy and provides additional safety checks compared with the volumetric alternative.

A Digital Home

The digital home for *PTR* has archived articles that can be shared via Facebook, Instagram, LinkedIn and X. Additionally, web-only news stories are posted regularly, and we plan to add more video interviews with the nation’s top pharmacy informatics experts. To access, click on the “Sections” tab on the main navigation bar on www.specialtypharmacycontinuum.com and choose “Pharmacy Technology Report.”

Twice a month, our *PTR* e-Newsletter features a mix of print and web-only content. Readers who sign up for the regular *SPC* or *PPN* e-Newsletter will automatically receive the *PTR* e-Newsletter. To register, click on the “Subscribe” tab in the top navigation bar of either site and choose “e-Newsletter.”

A Proven Formula

PTR is mailed with *SPC* and *PPN*. As a result, *PTR* benefits from powerful ride-along readership and exposure.

We are continuing to hone the editorial mission of *PTR*, so please send your ideas and feedback to Kate Baggaley, who coordinates *PTR* coverage, at kbaggaley@mcmahonmed.com. *PTR* also welcomes contributed articles from pharmacists with informatics expertise, so send Kate your topic ideas for consideration.

AT A GLANCE

545 W. 45th Street, 8th Floor
New York, NY 10036
Phone: (212) 957-5300
Fax: (212) 957-7230
pharmacypracticenews.com

VP EDITORIAL

David Bronstein
davidb@mcmahonmed.com

GROUP PUBLICATION DIRECTOR

Dave Kaplan
dkaplan@mcmahonmed.com
(973) 885-2315

SENIOR EDITOR

Marie Rosenthal
mrosenthal@mcmahonmed.com

DEPUTY MANAGING EDITOR

Kate Baggaley
kbaggaley@mcmahonmed.com

MANAGER, PUBLICATION SALES

Lillie Onday
londay@mcmahonmed.com
(732) 979-7009



Special Issue or Supplement –
NE Regional Silver

